Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Leukocyte Disease Clear all
Completed No phase listed Observational

Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

NCT00897923
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer
Interventions
radionuclide imaging, indium In 111-labeled autologous peripheral blood mononuclear cells, indium In 111-labeled autologous polymorphonuclear leukocytes
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

NCT00919503
View directory record Official record
Conditions
Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Procedure · Biological · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease

NCT02234934
View directory record Official record
Conditions
Granulomatous Disease, Chronic, X-linked
Interventions
Lentiviral G1XCGD Gene Therapy
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
23 Months and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Active, not recruiting Phase 3 Interventional

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

NCT06596252
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Budesonide
Drug
Lead sponsor
Dr. Falk Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy

NCT04384809
View directory record Official record
Conditions
Lateral Epicondylitis (Tennis Elbow)
Interventions
Leukocyte rich platelet rich plasma, Percutaneous Tenotomy
Biological · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 15, 2026, 4:15 PM EDT
Not listed No phase listed Observational

Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders

NCT00004341
View directory record Official record
Conditions
X-Linked Agammaglobulinemia, X-Linked Hyper IgM Syndrome, Wiskott-Aldrich Syndrome, Leukocyte Adhesion Deficiency Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

NCT00092937
View directory record Official record
Conditions
Granulomatous Disease, Chronic
Interventions
Busulfan
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 4:15 PM EDT
Completed No phase listed Observational

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

NCT06172751
View directory record Official record
Conditions
Hypereosinophilic Syndrome (HES)
Interventions
no intervention
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

NCT06429800
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
ATA3219
Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Busulfan, Fludarabine, r-ATG, Hematopoietic Cell Transplant, Tacrolimus, Methotrexate, Standard of Care, Alemtuzumab, Total Body Irradiation (TBI), Sirolimus, Melphalan, G-CSF
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
15 Years to 40 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
35
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

NCT03278912
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 15, 2026, 4:15 PM EDT
Completed No phase listed Observational

Natural History of Eosinophilic Esophagitis

NCT03290482
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Barium Esophagram, EsophaCap, Physical Examination and Questionnaires
Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 15, 2026, 4:15 PM EDT
Completed No phase listed Observational

Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients

NCT00460122
View directory record Official record
Conditions
Healthy, Transfusion Reactions
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 15, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

NCT06802315
View directory record Official record
Conditions
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
Interventions
Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)
Radiation · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Recruiting No phase listed Observational

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

NCT02523118
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2051
U.S. locations
19
States / cities
Phoenix, Arizona • Rogers, Arkansas • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers

NCT00900497
View directory record Official record
Conditions
Solid Tumors
Interventions
White Blood Cells/Granulocytes
Biological
Lead sponsor
Dipnarine Maharaj
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

NCT02778867
View directory record Official record
Conditions
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE)
Interventions
1 Food Elimination Diet Therapy, 6 Food Elimination Diet Therapy, 6 Food Elimination Diet (after 1FED failure), Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)
Other · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

NCT05201911
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
124I-AT03
Drug
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 15, 2026, 4:15 PM EDT
Recruiting No phase listed Observational

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

NCT04528355
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Interventions
data collection
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

NCT00002126
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Filgrastim
Drug
Lead sponsor
Amgen
Industry
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

NCT00684008
View directory record Official record
Conditions
AML, CML, MDS
Interventions
CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107)
Drug
Lead sponsor
Cytheris, Inc.
Industry
Eligibility
15 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 15, 2026, 4:15 PM EDT
Completed No phase listed Observational

Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies

NCT00727285
View directory record Official record
Conditions
Cystic Fibrosis, Pulmonary Exacerbation
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 4:15 PM EDT